Source:http://linkedlifedata.com/resource/pubmed/id/11162313
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2001-2-22
|
| pubmed:abstractText |
On the basis of the susceptibility of normal myelomonocytic cells to adenoviral vectors, we have studied the possibility of selectively transducing myelomonocytic murine leukemic cells (WEHI-3B) with regular (Reg-Ad) and genetically modified (RGD-Ad) adenoviral vectors. An 8-h incubation of WEHI-3B cells with 100 pfu of Reg-Ad vectors/cell resulted in the whole population becoming positive for transgene expression. Under identical conditions of infection, 20-30% of mouse bone marrow (BM) cells were positive for the transgene. When RGD-Ad vectors were used, a brief exposure (10 min) of WEHI-3B cells to 150 pfu of the virus/cell was enough for 100% of the leukemia cells to become positive for the marker transgene (EGFP). Under these conditions, only 15-20% of BM cells and of primitive hematopoietic progenitors (Lin(-)Sca-1(+) cells) became EGFP(+), indicating an improved selectivity of the vectors for the leukemic cells. The incubation of WEHI-3B but not normal BM cells with soluble fiber protein (FP) inhibited the infection with Reg-Ad. The use of the RGD-Ad bypassed the FP-CAR interaction required for the transduction of WEHI-3B cells with Reg-Ad, suggesting that the abrogation of this requirement accounts for the improved infectivity of these leukemic cells and for the selectivity of RGD-Ad in targeting WEHI-3B leukemia cells.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1525-0016
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
3
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
70-7
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:11162313-Adenoviridae,
pubmed-meshheading:11162313-Animals,
pubmed-meshheading:11162313-Bone Marrow Cells,
pubmed-meshheading:11162313-Cells, Cultured,
pubmed-meshheading:11162313-Flow Cytometry,
pubmed-meshheading:11162313-Gene Therapy,
pubmed-meshheading:11162313-Genetic Vectors,
pubmed-meshheading:11162313-Hematopoietic Stem Cells,
pubmed-meshheading:11162313-Kinetics,
pubmed-meshheading:11162313-Leukemia,
pubmed-meshheading:11162313-Mice,
pubmed-meshheading:11162313-Mice, Inbred BALB C,
pubmed-meshheading:11162313-Oligopeptides,
pubmed-meshheading:11162313-Protein Structure, Tertiary,
pubmed-meshheading:11162313-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:11162313-Time Factors,
pubmed-meshheading:11162313-Transduction, Genetic,
pubmed-meshheading:11162313-Transgenes,
pubmed-meshheading:11162313-Tumor Cells, Cultured,
pubmed-meshheading:11162313-beta-Galactosidase
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Selective transduction of murine myelomonocytic leukemia cells (WEHI-3B) with regular and RGD-adenoviral vectors.
|
| pubmed:affiliation |
Programa de Terapia Génica, CIEMAT, and Fundación Marcelino Botín, Madrid, 28040, Spain.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|